For each of the HER2-amplified breast cancer cell lines tested— SUM-225 and SUM-190— loss of viability was observed for single agent treatment with CAT-SKL, and treatment with HER2-specific SMKI CP724,714 appeared to induce a maximum effect. This evidence concerns the gene ERBB2 and breast carcinoma.